Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Polycystic Ovary Syndrome 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Breast Neoplasms 3Neoplasms 2Fatigue 2Weight Loss 1Systemic carnitine deficiency 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Pain 1Neurotoxicity Syndromes 1Muscular Atrophy 1Muscle Weakness 1Motor Activity 1Malnutrition 1Leukemia, Biphenotypic, Acute 1Insulin Resistance 1Hyperbilirubinemia 1Hyperandrogenism 1Hirsutism 1Heart Failure 1Gastrointestinal Stromal Tumors 1Dyslipidemias 1Depression 1Cardiotoxicity 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Basal Cell 1Cachexia 1Burkitt Lymphoma 1Basal Cell Nevus Syndrome 1

Interventions

Echocardiography 4sacubitril and valsartan sodium hydrate drug combination 3Standard of Care 3Nutrition Assessment 3Exercise 3Electrocardiography 3Carvedilol 3dapagliflozin 2Surveys and Questionnaires 2Spironolactone 2Rituximab 2Lenalidomide 2Ivabradine 2Control Groups 2Blood Specimen Collection 2Atorvastatin 2Adrenergic beta-Antagonists 2ziprasidone 1pertuzumab 1pegfilgrastim 1obinutuzumab 1nicotinamide-beta-riboside 1empagliflozin 1candesartan 1acalabrutinib 1Zolpidem 1Watchful Waiting 1Warfarin 1Vincristine 1Vecuronium Bromide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Heart Failure × Carnitine × Clear all
NCT00247975 2022-08-16

Ability of L-carnitine to Prevent Heart Damage in Breast Cancer Patients Receiving Anthracycline Chemotherapy

Ottawa Heart Institute Research Corporation

Phase 2/3 Terminated
36 enrolled
Breast

Breast Neoplasms, Heart Failure

Data powered by HemOnc (CC BY 4.0) Colophon âš¡